Dr. Verschraegen on the Need to Address TRAEs of Immunotherapy in Melanoma

Claire F. Verschraegen, MD, professor of Medicine, director of the Division of Medical Oncology, the Ohio State University College of Medicine, Diane Nye and Michael Rayden chair in Innovative Cancer Research, director for translational research, the Ohio State University Comprehensive Cancer Center (OSUCCC)– James, discusses the need to improve the management of treatment-related adverse effects (TRAEs) of immunotherapy in melanoma.

Read More
MRV News
Melanoma News